Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054834 · ClinicalTrials.gov registry record · Phase 1
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00054834 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 27 participants.
The verdict
NCT00054834, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.
Interventions
- DRUG hLL2 (epratuzumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054834
The ClinicalTrials.gov registry entry for NCT00054834 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hLL2 (epratuzumab) is the first listed.
NCT00054834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054834 about?
NCT00054834 is a clinical study titled "Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma". The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.
What is the current status of trial NCT00054834?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2003-03.
What interventions are being tested in trial NCT00054834?
The interventions under investigation include: hLL2 (epratuzumab) (DRUG).
Who is sponsoring clinical trial NCT00054834?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.